Since the T-Fc employs multiple endocytic pathways, T-Fc-FGFR1 complexes are less prone to alterations in protein trafficking in cancer cells, suggesting that the T-Fc could constitute highly attractive drug carrier for ADC approach. Here, FGFR1 is linked to cancer.